- About EMBARC
- Patient Resource
- Registry Documents
- EMBARC Registry
The largest prospective registry of bronchiectasis globally with an initial report of 16,963 patients from 28 countries has now been published. It describes the frequency of different aetiologies, microbiology, treatments, and disease burden in terms of lung function, exacerbation frequency, hospitalisations and disease severity.
In most cases, the cause of bronchiectasis is unknown. Where aetiology has been confirmed, postinfective bronchiectasis is the most common.
Bronchiectasis severity as determined by the Bronchiectasis Severity Index (BSI) also shows geographical variation.
Microbiology data shows Pseudomonas aeruginosa and Haemophilus influenzae outnumber all other pathogens isolated from patient samples.
EMBARC is a pan-European network committed to promoting clinical research and education in bronchiectasis, through sharing of protocols, research idea and expertise. Central to this project is the creation of the European Bronchiectasis Registry, a collaboration open to all investigators around Europe caring for patients with bronchiectasis.
The 3rd European Bronchiectasis Workshop (EBROW23) is being held in Milan, February 23-25th 2023. The programme is available to view online and there is still time to register your …Read More
Following the success of the previous two bronchiectasis patient conferences, EMBARC clinicians have continued to work with the ELF patient advisory group to develop the 3rd …Read More